In summary, these data indicate that increased tolerance to replicative and oxidative stress through DDR activation and BCL-2 overexpression could be a unifying feature of poor prognosis MYC positive DLBCL subsets such as ABC and HG-BCL w/DH, which could be the basis for a tailored therapeutic approach. This evidence concerns the gene BCL2 and diffuse large B-cell lymphoma.